Correction

Alemtuzumab for Refractory Celiac Disease in a Patient at Risk for Enteropathy-Associated T-Cell Lymphoma

N Engl J Med 2006; 355:856August 24, 2006

Article

Alemtuzumab for Refractory Celiac Disease in a Patient at Risk for Enteropathy-Associated T-Cell Lymphoma (Correspondence, N Engl J Med 2006:354;2514 - 2515) . On page 2514 of the letter, the sentence that begins three lines from the bottom of the right-hand column should have read, “Alemtuzumab was administered according to the conventional therapeutic schedule used in cases of chronic lymphocytic leukemia that is resistant to alkylating agents (30 mg three times per week for 12 consecutive weeks),” not “(30 mg two times per week for 12 consecutive weeks),” as printed.